Disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992
Glenmark Pharmaceuticals Ltd has submitted the disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 199206-08-2014
06-08-2014
Updates on Disclosure of Voting results of AGM (Clause 35A)
With reference to the earlier announcement dated July 26, 2014 regarding the disclosure made by the Company pursuant to Clause 35A of the listing agreement pertaining to outcome of the AGM held on July 25, 2014, Glenmark Pharmaceuticals Ltd has now informed BSE that in disclosure uploaded, the page number four (i.e. Resolution Nos. 8, 9 & 10) had been missed out inadvertently....28-07-2014
Disclosure of Voting results of AGM (Claue 35A)
Glenmark Pharmaceuticals Ltd has informed BSE regarding the details of Voting results at the 36th Annual General Meeting (AGM) of the Company held on July 25, 2014, under Clause 35A.26-07-2014
Outcome of AGM
Glenmark Pharmaceuticals Ltd has informed BSE that the Annual General Meeting (AGM) of the Company was held on July 25, 2014.25-07-2014
Outcome of Board Meeting
Glenmark Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company, at its Meeting held on July 24, 2014 allotted 24,100 equity shares to the employees of the Company on exercise of options granted to them pursuant to ESOS 2003.24-07-2014
Announces Q1 results, Results Press Release, Management Discussion & Analysis and Limited Review Report for the Quarter ended June 30, 2014
Glenmark Pharmaceuticals Ltd has announced the following results for the quarter ended June 30, 2014:The Unaudited Standalone results for the Quarter ended June 30, 2014The Company has posted a net profit of Rs. 1039.34 million for the quarter ended June 30, 2014 as compared to Rs. 1177.99 million for the quarter ended June 30, 2013. Total Income has increased from Rs. 5315.90 million for the quarter ended June 30, 2013 to Rs. 6317.00 million for the quarter ended June 30, 2014....24-07-2014
Glenmark Pharmaceuticals to set up a new manufacturing facility in the US
Glenmark Pharmaceuticals Ltd has informed BSE regarding a Press Release dated July 17, 2014, titled 'Glenmark Pharmaceuticals to set up a new manufacturing facility in the US".17-07-2014
Closure of Trading Window
Glenmark Pharmaceuticals Ltd has informed BSE that as per the "Code of Conduct for Prevention of Insider Trading" of the Company, the trading window shall remain closed for Directors and other designated employees of the Company from July 16, 2014 to July 25, 2014 (both days inclusive) for the purpose of approval of the Company's Un-audited Financial Statements for the First Quarter ended June 30, 2014.15-07-2014
Q1 results on July 24, 2014
Glenmark Pharmaceuticals Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on July 24, 2014, to consider and approve the Company's Un-audited Financial Statements for the First Quarter ended June 30, 2014 (Q1).15-07-2014
Glenmark Generics receives final ANDA approval for Fluocinonide Cream
Glenmark Pharmaceuticals Ltd has informed BSE regarding a Press Release dated July 15, 2014, titled "Glenmark Generics receives final ANDA approval for Fluocinonide Cream"15-07-2014